Answers are grounded in this paper and cite their sources.
Extract GLP-1 receptor agonists (GLP-1RAs) have been used for around twenty years in the treatment of type 2 diabetes. Extensive research programs have since evaluated the effect of higher doses to repurpose these molecules in the treatment of obesity and its complications. The observed effects on weight loss range from −6% to −20% of total body weight, depending on the molecules studied. Through this weight loss, but also likely via other processes, GLP-1RAs protect renal function, improve metabolic associated steato-hepatitis (MASH), heart failure and knee osteoarthritis, and reduce the risk of cardiovascular events [1].
No takes yet. Share an insight, caveat, or question.
Quema et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: